JP2018502600A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502600A5
JP2018502600A5 JP2017552233A JP2017552233A JP2018502600A5 JP 2018502600 A5 JP2018502600 A5 JP 2018502600A5 JP 2017552233 A JP2017552233 A JP 2017552233A JP 2017552233 A JP2017552233 A JP 2017552233A JP 2018502600 A5 JP2018502600 A5 JP 2018502600A5
Authority
JP
Japan
Prior art keywords
lactic acid
plasmid
seq
amino acid
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017552233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502600A (ja
JP6581208B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/081146 external-priority patent/WO2016102660A1/en
Publication of JP2018502600A publication Critical patent/JP2018502600A/ja
Publication of JP2018502600A5 publication Critical patent/JP2018502600A5/ja
Application granted granted Critical
Publication of JP6581208B2 publication Critical patent/JP6581208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017552233A 2014-12-23 2015-12-23 創傷治癒の方法 Active JP6581208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1451658 2014-12-23
SE1451658-7 2014-12-23
PCT/EP2015/081146 WO2016102660A1 (en) 2014-12-23 2015-12-23 Methods for wound healing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019156412A Division JP7033109B2 (ja) 2014-12-23 2019-08-29 創傷治癒の方法

Publications (3)

Publication Number Publication Date
JP2018502600A JP2018502600A (ja) 2018-02-01
JP2018502600A5 true JP2018502600A5 (enExample) 2018-03-22
JP6581208B2 JP6581208B2 (ja) 2019-09-25

Family

ID=55080095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017552233A Active JP6581208B2 (ja) 2014-12-23 2015-12-23 創傷治癒の方法
JP2019156412A Active JP7033109B2 (ja) 2014-12-23 2019-08-29 創傷治癒の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019156412A Active JP7033109B2 (ja) 2014-12-23 2019-08-29 創傷治癒の方法

Country Status (9)

Country Link
US (3) US10696974B2 (enExample)
EP (2) EP3237622B1 (enExample)
JP (2) JP6581208B2 (enExample)
KR (2) KR102297619B1 (enExample)
CN (2) CN107208107B (enExample)
AU (2) AU2015370982B2 (enExample)
CA (1) CA2971520C (enExample)
ES (2) ES3048233T3 (enExample)
WO (1) WO2016102660A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132202A1 (en) 2016-01-25 2017-08-03 Nant Holdings Ip, Llc Nk cells with altered cxcl12/cxcr4 signaling
WO2018081196A1 (en) * 2016-10-31 2018-05-03 Kimberly-Clark Worldwide, Inc. Method for archiving a microbiome
US20240024388A1 (en) * 2017-02-17 2024-01-25 The University Of British Columbia Probiotic compositions and uses thereof
CN110157733A (zh) * 2018-02-11 2019-08-23 四川大学 重组mIL-22BP载体、脂质体复合物及其制备方法和用途
JP2021531015A (ja) * 2018-07-24 2021-11-18 バイオガイア・エイビーBiogaia AB アデノシンレベルを増加させることができる細菌株を使用する治療法
EP3701051B1 (en) 2018-07-24 2022-07-13 Biogaia AB Selection and use of melatonin supporting bacteria to reduce infantile colic
CN109112155A (zh) * 2018-08-02 2019-01-01 南昌大学 乳酸乳球菌mg1363的构建及其在治疗细菌性阴道炎中的应用
CN109234298A (zh) * 2018-10-30 2019-01-18 南昌大学 一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用
CN109517772A (zh) * 2018-10-30 2019-03-26 南昌大学 一种乳酸乳球菌mg1363的构建及其在治疗产妇乳头皲裂中的应用
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
BR112021023682A2 (pt) 2019-06-24 2022-04-12 Mendes Srl Composição com ação antibacteriana e de reepitelização incluindo probióticos
CN110623792B (zh) * 2019-09-23 2022-05-06 温州医科大学附属第一医院 一种医学敷料及其制备方法
CN114470007B (zh) * 2020-11-13 2024-10-18 葡萄王生技股份有限公司 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途
EP4417684A4 (en) 2021-10-11 2026-03-25 Ajinomoto Kk BACTERIA MODIFIED TO EXPRESS A PROTEIN TAT HETEROLOGUE
WO2023118327A1 (en) 2021-12-22 2023-06-29 Ilya Pharma Ab Live bacteria as excipients for proteins
US20250339477A1 (en) * 2021-12-29 2025-11-06 Ilya Pharma Ab Treatment of therapy-induced enteropathy
KR102752056B1 (ko) * 2023-07-12 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리(Lactobacillus reuteri) NCHBL-005 균주를 포함하는 창상 예방 또는 치료, 피부 재생 촉진용 조성물
GB202405882D0 (en) 2024-04-26 2024-06-12 Ilya Pharma Ab Treatment of mdr infections
CN118948906B (zh) * 2024-10-16 2025-02-14 温州医科大学附属第一医院 一种促进创面愈合的乳酸杆菌生物膜衍生物及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
CA2279461A1 (en) * 1997-02-07 1998-08-13 Shionogi & Co., Ltd. Novel mouse cxc chemokine receptor
PT1739178E (pt) 1999-07-05 2010-11-17 Actogenix Nv Libertação de péptidos trifólios
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
US9200249B2 (en) 2004-08-20 2015-12-01 Actogenix N.V. Method to improve Lactococcus preservation
US9017662B2 (en) 2005-08-30 2015-04-28 Actogenix N.V. Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
WO2007039586A1 (en) 2005-10-03 2007-04-12 Actogenix Nv Use of recombinant yeast strain producing an anti -inflammatory compound in the manufacture of a medicament to treat colitis
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
US20110183319A1 (en) 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
RU2008147398A (ru) 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
WO2008071751A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
US20100143447A1 (en) 2006-12-19 2010-06-10 Ferrosan A/S Wound or tissue dressing comprising lactic acid bacteria
JP2010512865A (ja) 2006-12-19 2010-04-30 フェロサン エーエス 乳酸菌を含む創傷または組織包帯
ES2595729T3 (es) 2007-01-12 2017-01-03 Intrexon Actobiotics Nv Promotores de Lactococcus y usos de los mismos
EP3351268B1 (en) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
WO2008155120A2 (en) 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
JP5248519B2 (ja) 2007-11-07 2013-07-31 小野薬品工業株式会社 Sdf−1を含有してなる徐放性組成物
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US8367109B2 (en) 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
WO2010034844A1 (en) 2008-09-29 2010-04-01 Actogenix N.V. Reduced colonization of microbes at the mucosa
WO2010077682A2 (en) * 2008-12-08 2010-07-08 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
JP2012524781A (ja) * 2009-04-21 2012-10-18 ユニバーシティー・オブ・マイアミ 虚血性及び糖尿病性創傷の治癒を促進する組成物、キット及び方法
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
KR101821417B1 (ko) 2009-04-30 2018-01-23 인트랙슨 액토바이오틱스 엔.브이. 유산균의 냉동건조에 사용하기 위한 냉동보호제
CN102459571B (zh) * 2009-06-04 2014-01-08 香港中文大学 抗炎细菌
CL2009001506A1 (es) 2009-07-01 2009-09-25 Univ Concepcion Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche.
JP5856059B2 (ja) 2009-08-28 2016-02-09 ザ クリーブランド クリニック ファウンデーション 虚血組織を治療するためのsdf−1送達
EP2483409B1 (en) 2009-09-29 2017-03-22 Intrexon Actobiotics NV LACTOBACILLUS glyceraldehyde-3-phosphate dehydrogenase PROMOTERS AND USES THEREOF
GB2482536B (en) * 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN101985052B (zh) 2010-08-31 2013-11-06 中国人民解放军第二军医大学 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法
PL2704704T3 (pl) 2011-05-03 2019-04-30 Dupont Nutrition Biosci Aps Bakterie probiotyczne do miejscowego leczenia zaburzeń skóry
RU2766157C2 (ru) 2011-06-01 2022-02-08 Интрексон Актобиотикс Н.В. Система полицистронной экспрессии для бактерий
DK2758512T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
CA2848471C (en) 2011-09-23 2021-11-16 Actogenix Nv Modified gram positive bacteria and uses thereof
GB201206599D0 (en) * 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
KR20160005333A (ko) * 2013-03-15 2016-01-14 유벤타스 세라퓨틱스, 인크. 흉터 형성을 완화시키기 위한 sdf-1의 용도
WO2014146202A1 (en) * 2013-03-18 2014-09-25 London Health Sciences Centre Research Inc. Bacteria for the prevention, treatment and diagnosis of breast cancer
EP3030232B1 (en) * 2013-04-29 2022-07-06 Medregen, LLC Wound healing via autologous stem cell mobilization
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction

Similar Documents

Publication Publication Date Title
JP6866974B2 (ja) 新規なエンドリシンポリペプチド
Borrero et al. Modified lactic acid bacteria detect and inhibit multiresistant enterococci
Nishie et al. Antibacterial peptides “bacteriocins”: an overview of their diverse characteristics and applications
JP2021501581A5 (enExample)
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
MX2018009225A (es) Inmunoterapia basada en vectores de distribución personalizados y usos de la misma.
Chen et al. Cloning and heterologous expression of a bacteriocin sakacin P from Lactobacillus sakei in Escherichia coli
HRP20241279T1 (hr) Pripravak koji sadrži probiotike koji prekomjerno eksprimiraju protein clpb za uporabu u liječenju pretilosti
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
RU2017142932A (ru) Фармацевтические и пищевые композиции для индуцирования насыщения и продления сытости у нуждающихся в этом субъектов
WO2017084985A1 (en) Bacteriocin composition and method
Sivaraj et al. Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
ES2808780T3 (es) Nuevos péptidos antimicrobianos, sus variantes y usos
MX2023015156A (es) Peptidos antimicrobianos modificados.
JP2013542942A5 (enExample)
WO2010012972A3 (en) Novel bacterial cells and uses thereof
Niu et al. Full‐length cDNA, prokaryotic expression, and antimicrobial activity of UuHb‐F‐I from Urechis unicinctus
Nes et al. Antimicrobial components of lactic acid bacteria
IL297430A (en) Chimeric endolysin polypeptide
Peng et al. Tissue distribution, expression, and antimicrobial activity of Anas platyrhynchos avian β-defensin 6
WO2019033007A3 (en) Staphylococcus pseudintermedius virulence factor compositions
WO2019059817A9 (en) VACCINE BASED ON FUSION PROTEIN AND PLASMIDIC DNA
CN107849103B (zh) 新抗微生物肽、它们的变体和用途
CN106749534B (zh) 一种许氏平鮋抗菌肽bs20及其应用
US11648289B2 (en) Antibacterial method